Miltefosine — The Long-Awaited Therapy for Visceral Leishmaniasis?

Publisher Website
Google Scholar
Abstract
Miltefosine was originally developed as an antineoplastic drug, but it has the potential to become the first highly effective, orally administered drug for treating visceral leishmaniasis, a life-threatening parasitic disease. We do not know whether additional clinical trials and experience with miltefosine will support the encouraging findings of the phase 2 study described by Jha et al. in this issue of the Journal. 1 However, the prospect of a new drug that is administered orally rather than parenterally is good news indeed, because the drug could markedly facilitate the treatment of patients.Although asymptomatic or subclinical infection is common in some . . .